MedPath

Study to compare two gels that are used to treat acne vulgaris. It will be compared the tolerability and effectivity following application of two combination topical acne products clindamycin 1% and 0.025% tretinoin gel (Acnatac® Gel), adapalen 0,1% and benzoyl peroxide 2,5% gel (Epiduo® Gel).

Active, not recruiting
Conditions
acne vulgaris
Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Registration Number
EUCTR2015-002699-26-DE
Lead Sponsor
GWT-TUD GmbH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Diagnosis of mild to moderate facial acne vulgaris at baseline- Age: 14 years to 50 years
- No evidence of facial irritation (erythema, dryness/scaling,
burning/itching/stinging) that is not typical for acne vulgaris
-Willingness to take part in acne study including screening visit and follow up visits on day 0,7, and 21
-No use of systemic antibiotics, steroids, retinoids and keratolytics within the last 30 days before start of the acne study
-Patients have to sign personally consent form and follow study procedures
-Patient is in good general health

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Female patients who were pregnant, planning to become pregnant or breastfeeding
-Sexually active female subjects do not use a medically acceptable form of contraception (oral contraception, injectable or implantable methods or intrauterine devices)
- Female patients who are in childbreaking years except
post-menopausal (12 Monate natürliche Amenorrhoe),
? postoperative (6 weeks after ovariectomy with or without hysterectomy)
-regulary and correct use of contraceptive with error rate < 1 %/year
-no sex
- vasectomy of the partner

- Diseases of the facial skin other than acne
-No concomitant topical medications (including make-up) or keratolytics as sulphur, salicylic acid, benzoyl peroxide, resorcin and abradents and acid-containing peels one week before the study starts
-Patients who had facial procedures (chemical peel, laser therapy, photodynamic therapy, microdermabrasion, or UV light therapy) within the past 4 weeks
-No concomitant participation in other studies within the past 30 days
-Hypersensitivity against any ingredients of Acnatac® -gel or Epiduo®gel
-Systemic medication with antibiotics or antibiotics within the last 4 weeks before study start
- Systemic medication with retinoids within the last 6 months before study start
-Topical treatment of acne vulgaris within the last two weeks before study
-Acne fulminans,
-Severe systemic disease respectively taking immunosuppressive drugs
-Severe liver disease
-Severe renal disease
-
-History or presence of regional enteritis or inflammatory bowel disease
-Other reasons that the doctor in charge decides about

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.